Dimensional Fund Advisors LP increased its position in AstraZeneca plc (NYSE:AZN) by 18.3% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,558,882 shares of the company’s stock after purchasing an additional 395,699 shares during the period. Dimensional Fund Advisors LP owned 0.10% of AstraZeneca worth $86,695,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of AZN. WFG Advisors LP boosted its stake in AstraZeneca by 36.0% in the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after acquiring an additional 984 shares during the period. Bronfman E.L. Rothschild L.P. boosted its stake in AstraZeneca by 71.2% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock valued at $145,000 after acquiring an additional 1,769 shares during the period. Quadrant Capital Group LLC boosted its stake in AstraZeneca by 18.4% in the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock valued at $147,000 after acquiring an additional 846 shares during the period. First Interstate Bank boosted its stake in AstraZeneca by 10.3% in the second quarter. First Interstate Bank now owns 5,127 shares of the company’s stock valued at $175,000 after acquiring an additional 480 shares during the period. Finally, FTB Advisors Inc. boosted its stake in AstraZeneca by 3.2% in the second quarter. FTB Advisors Inc. now owns 6,471 shares of the company’s stock valued at $197,000 after acquiring an additional 200 shares during the period. Institutional investors and hedge funds own 14.75% of the company’s stock.
A number of equities analysts have commented on AZN shares. Sanford C. Bernstein restated a “buy” rating on shares of AstraZeneca in a research note on Friday, September 22nd. BMO Capital Markets restated a “buy” rating and issued a $38.00 target price on shares of AstraZeneca in a research note on Tuesday, November 7th. Citigroup upgraded AstraZeneca to a “buy” rating in a research note on Wednesday, October 18th. Natixis upgraded AstraZeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 6th. Finally, Argus restated a “buy” rating and issued a $35.00 target price on shares of AstraZeneca in a research note on Friday, September 1st. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $34.20.
AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.55. The company had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $6 billion. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.32 earnings per share. sell-side analysts forecast that AstraZeneca plc will post 1.87 EPS for the current year.
WARNING: This piece of content was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/23/dimensional-fund-advisors-lp-boosts-position-in-astrazeneca-plc-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.